Month: March 2022

EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans Company to focus R&D resources primarily on VIITAL™ data readout while actively pursuing potential commercialization partner for EB-101; maintain focus on preclinical eye gene therapy programs Pursue strategic partner to take over development activities for ABO-102 for MPS IIIA, while discontinuing development of ABO-101 for MPS IIIB Reduce operating expenses and extend cash runway to mid-2023 $50.9 million in cash resources as of December 31, 2021 Conference call scheduled for today at 8:30 a.m. ET NEW YORK and CLEVELAND, March 31, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated...

Three years sales and net income in $ million Three years sales and net income in $ millionMONTREAL, March 31, 2022 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG) (Dynacor or the Corporation) released its audited annual consolidated financial statements and the management’s discussion and analysis (MD&A) for the year ended December 31, 2021. These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com. (All figures in this press release are in Ms of US$ unless stated otherwise. All amounts per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding).  2021 OVERVIEW AND HIGHLIGHTS OVERVIEW Dynacor completed 2021 with both production and financial historical high...

SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona” or the ‎‎“Company”) (TSXV:SGMD), ‎an acquisition-oriented medical device company serving the global injury and surgery recovery (known as recovery science) market, announced today preliminary financial results for its fiscal fourth quarter ending February 28, 2022. Salona posted revenue growth of 52% quarter-over-quarter in Q4 and 44% gross profit growth for the same period.Revenues (preliminary, pre-audit) increased from $5,286,702 to roughly $8,029,000 or a 52% increase from last quarter. Gross profit (preliminary, pre-audit) increased from $1,662,636 to roughly $2,402,000 or 44% increase from last quarter. The Company’s cash balance (including liquid investments and restricted cash) was approximately $8,500,000 as of February 28,...

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, today released its fourth quarter and full year 2021 financial results. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars except common shares (“Shares”) and per Share amounts. 2021 HighlightsRecorded net revenues of $83.8 million in 2021, an increase of 79% compared to 2020;Fourth quarter net Cannabis revenues of $29.3 million, a 20% increase QoQ; Maintained the #1 LP position in Canada for Cannabis 2.0 product sales1 in 2021, increasing its market share to approximately 15% (up from 14% in 2020); Continued to dominate...

Revenues for Full Year 2021 and 4th Quarter 2021: $10.5M and $7.5M209% and 280% over same periods in 2020  SUNRISE, Fla., March 31, 2022 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (“Nano Dimension” or the “Company”) (Nasdaq: NNDM), an industry-leader in Additively Manufactured Electronics (AME), Printed Electronics (PE), and Micro Additive Manufacturing (Micro-AM), today announced a preview of its financial results for the fourth quarter and full year ended December 31st, 2021.  Nano Dimension reported audited consolidated revenues of $7.5 million for the fourth quarter ended December 31st, 2021, a 280% increase over the fourth quarter of 2020 and 460% increase over the third quarter of 2021. Revenues for the full year ended December 31st, 2021, were $10.5 million, an increase of 209% over full year 2020. Consolidated cash and deposits...

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided key business updates. “This past quarter caps a very productive year for Windtree with progress towards multiple value-creating milestones, making for an exciting 2022. We are pleased to have successfully completed enrollment in our phase 2 study of istaroxime, our lead clinical program in early cardiogenic shock, and plan to announce topline data in April 2022. Cardiogenic shock represents a great opportunity for Windtree. It has significant unmet need, a potentially supportive scale and a regulatory pathway...

Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022 Presented interim data in December 2021 of the combination study of AFM13 with NK cells (AFM13-104), showing 100% ORR after one treatment cycle at the highest NK cell dose. Data after two treatment cycles will be presented orally at the AACR Clinical Trials Plenary session on April 10, 2022 Initiated enrollment in the expansion phase of the AFM24-101 monotherapy trial at the recommended phase 2 dose (RP2D); a poster from the dose escalation will be presented at AACR on April 11, 2022 Enrollment is underway in two separate phase 1/2a studies investigating AFM24 in combination with atezolizumab (AFM24-102) and SNK01 NK cells (AFM24-103) IND filing for AFM28, a CD123/CD16A innate cell engager (ICE®) for AML, is expected...